Previous 10 | Next 10 |
100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...
Amryt Supports Rare Disease Day 202 2 DUBLIN, Ireland, and Boston MA, February 2 5 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare dis...
A mryt to Report FY and Q4 202 1 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23 , 202 2 , Amryt (Nasdaq: AMYT ) a global, commercial-stage ...
Amryt Completes $125 Million Non-Dilutive Debt Ref inancing New Facilities Will Significantly Reduce Amryt’s Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027 Further St rengthen...
Krystal produced excellent phase 3 data. It has major competitive advantages over peers. The company is flush with cash. For further details see: Krystal Biotech: The Future Looks More And More Derisked
Notice of General Meeting Amryt seeking shareholder approval for share buybacks and routine matters DUBLIN, Ireland, and Boston MA, February 1, 2022 , Amryt Pharma plc (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedi...
Amryt Announces Oleogel-S10 EMA Regulatory Update Ad-Hoc Expert Group to provide independent EB specific expertise and advice DUBLIN, Ireland, and Boston MA, January 28, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquirin...
Amryt Announces New Patents for Oleogel-S10 DUBLIN, Ireland, and Boston MA, January 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an up...
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Acromegal...
Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6 , 2022 , Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“ Amryt ” or the “ Company ...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...